Revolution Medicines (RVMD) has provided an announcement.
The board of a company expanded its size to ten directors and welcomed Frank K. Clyburn, Jr. as a new independent director, set to serve until the 2025 annual stockholders’ meeting. Clyburn brings extensive experience from his CEO role at International Flavors & Fragrances and leadership positions at Merck, Sanofi Aventis, and Marion Laboratories, as well as past board membership at DuPont de Nemours. His appointment comes with an equity incentive package, comprising stock options and restricted stock units, vesting over three years, alongside standard director compensation and indemnification agreements.
For an in-depth examination of RVMD stock, go to TipRanks’ Stock Analysis page.
